Clinical trials: Parkinsons Disease (PD)
Parkinson Disease
A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)
This is a one year, 2-part study to determine the efficacy and safety of preladenant, an adenosine type 2a (A2a) receptor antagonist.
- Trial name
- PARADYSE (NCT01155479)
- Testing
- Preladenant 2 mg tablet, Preladenant 5 mg tablet, Preladenant 10 mg tablet
- Volunteers
- 1,022 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease(PD)
Adaptive DBS for PD
The goal of this clinical trial is to evaluate the efficacy and safety of an adaptive deep brain stimulation (aDBS) system for managing Parkinson's disease symptoms.
- Trial name
- SMART-DBS (NCT07635823)
- Testing
- adaptive deep brain stimulation, conventional deep brain stimulation
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Parkinson Disease
Opicapone Treatment Initiation Open-Label Study
This is an observational study to describe the treatment patterns and clinical outcomes observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients experiencing "off" episodes with…
- Trial name
- OPTI-ON (NCT04787965)
- Testing
- Opicapone
- Where
- 6 sites in United States
- Volunteers
- 239 people
- Sponsor
- Neurocrine Biosciences
Parkinson's Disease (PD)
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
The main goal of the study is to investigate how well the new drug SUL-238 works in Parkinson's Disease (PD). This is done by means of an MRS scan. An MRS scan is similar to a regular MRI scan.
- Trial name
- SHEPHERD (NCT07322887)
- Testing
- SUL-238 (1500 mg t.i.d.) film-coated tablets, SUL-238 (500 mg t.i.d.) film-coated tablets
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.
Parkinson Disease
NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa
A 28-day phase 2a, double-blind, placebo-controlled (1:1), multi-center study of 20 mg NE3107, twice daily of safety, potential drug-drug interactions, and MDS-UPDRS defined activity in patients with Parkinson's disease .
- Trial name
- NCT05083260
- Testing
- NE3107
- Where
- 16 sites in United States
- Volunteers
- 46 people
- Sponsor
- BioVie Inc.
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Parkinson Disease, Movement Disorders
Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study
This study is an extension to the HP-CD-CL-2002 clinical study. It evaluates the long-term safety and tolerability of CDNF in patients with Parkinson's disease when dosed directly into the brain using an implanted investigational…
- Conditions
- Parkinson Disease, Movement Disorders, Neuro-Degenerative Disease, Nervous System Diseases
- Trial name
- NCT03775538
- Testing
- Cerebral Dopamine Neurotrophic Factor, Renishaw Drug Delivery System
- Where
- 3 sites in Finland, Sweden
- Volunteers
- 15 people
- Sponsor
- Herantis Pharma Plc.
Parkinson's Disease (PD)
Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients
The purpose of this study is to determine the effect of two different multiple-dose regimens of nebicapone in comparison to placebo and entacapone 200 mg on the pharmacokinetics of levodopa in Parkinson's Disease (PD) patients.
- Trial name
- NCT02834507
- Testing
- BIA 3-202, Comtan®, Sinemet®
- Volunteers
- 19 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease (PD)
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).
- Trial name
- NCT06773962
- Testing
- TB006
- Where
- 14 sites in United States
- Volunteers
- 62 people
- Sponsor
- TrueBinding, Inc.
Parkinson's Disease
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an estimated incidence of 4.5-16/100,000 persons/year.
- Trial name
- BIPARKII (NCT01227655)
- Testing
- BIA 9-1067, Levodopa, Carbidopa
- Where
- Portugal
- Volunteers
- 427 people
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
FitMi PD Home Therapy for Parkinson's Disease
The investigators will run an at-home usability study of a newly developed home exercise device (FitMi PD) for individuals with Parkinson's disease.
- Trial name
- NCT05655377
- Testing
- FitMi PD
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Flint Rehabilitation Devices, LLC
Parkinsons Disease (PD)
A Study of NE3107 in Early Parkinson's
The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for…
- Trial name
- SUNRISE-PD (NCT06757010)
- Testing
- NE3107
- Where
- 4 sites in United States
- Volunteers
- 57 people
- Sponsor
- BioVie Inc.
Early Stage Parkinson's Disease
An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial
- Trial name
- NCT00335374
- Testing
- Pardoprunox
- Where
- 75 sites in United States, Australia and 13 more
- Volunteers
- 202 people
- Sponsor
- Solvay Pharmaceuticals
Parkinson's Disease
Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study
The purpose of the study is to evaluate the effectiveness of the Medtronic Adaptive DBS therapy (aDBS) for Parkinson's Disease in China with the Percept family of Implantable Neurostimulators (Percept PC and Percept RC).
- Trial name
- NCT07216976
- Testing
- Percept™ PC and Percept RC with Adaptive DBS (aDBS™)
- Where
- 5 sites in China
- Volunteers
- 61 people
- Sponsor
- MedtronicNeuro
Parkinson Disease
A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD
A Study to evaluate the add-on efficacy and safety of opicapone 50 mg or an extra dose of L-DOPA 100 mg for the treatment of wearing-off in patients with PD.
- Trial name
- NCT04821687
- Testing
- Ongentys 50mg, Madopar Tab. 125 or Perkin Tab. 25-100mg
- Where
- South Korea
- Volunteers
- 169 people
- Sponsor
- SK Chemicals Co., Ltd.
Parkinson's Disease (PD)
COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
The purpose of this study is to evaluate treatment of advanced Parkinson's Disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) monotherapy in a routine clinical setting.
- Trial name
- COSMOS (NCT03362879)
- Where
- 30 sites in Austria, Canada and 9 more
- Volunteers
- 412 people
- Sponsor
- AbbVie
Parkinson's Disease, Dementia
Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia
The purpose of this study is to evaluate the safety, tolerability, and efficacy of donepezil (Aricept) in Parkinson's Disease (PD) patients with dementia.
- Trial name
- NCT01327859
- Testing
- Prior Donepezil 5mg, Prior Donzepezil 10mg
- Where
- United Kingdom
- Volunteers
- 357 people
- Sponsor
- Eisai Inc.
Parkinson Disease
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa…
- Trial name
- NCT07432958
- Testing
- AP-472
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Appello Pharmaceuticals, Inc.
Advanced Parkinson's Disease
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD.
- Trial name
- NCT02549092
- Testing
- Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube
- Where
- 38 sites in United States, Australia and 7 more
- Volunteers
- 89 people
- Sponsor
- AbbVie
Parkinson Disease
Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)
This study was designed to evaluate the pharmacokinetic profile, safety and efficacy in Parkinson's Disease patients.
- Trial name
- NCT00434304
- Testing
- Ropinirole prolonged release/extended release(PR/XR)
- Where
- 12 sites in Japan
- Volunteers
- 62 people
- Sponsor
- GlaxoSmithKline